Hims & Hers Super Bowl Ad Promotes Galleri Test with Low 40% Detection Rate
Hims & Hers aired a Super Bowl ad for Grail’s Galleri blood test, scanning over 50 cancer types but detecting only ~40% per October 2025 data, missing more than half of cases. Subscribers will pay $700 for the test via the $350 lab service and FDA review is pending.
1. Super Bowl Ad Promotes Galleri Multi-Cancer Test
Hims & Hers ran a Super Bowl commercial in early February spotlighting Galleri, a blood test that screens for over 50 cancers, including hard-to-detect pancreatic and ovarian tumors. Interim October 2025 data indicate a ~40% detection rate, missing over half of cases, while subscribers will pay $700 for the test through the company's $350 lab service and FDA approval remains pending.
2. Reliability Concerns and Regulatory Pressures
Critics warn that the ad’s “no cancer signal detected” message could give patients false reassurance given the test’s limited sensitivity. The company also paused its $49 compounded Wegovy offering after FDA warnings, reported a Q3 EPS of $0.06 versus estimates and $598.97 million in revenue, guided Q4 below consensus, and has seen its stock fall roughly 49% over the past year.